Advertisement

American Journal of Clinical Dermatology

, Volume 5, Issue 3, pp 199–203 | Cite as

Acanthosis Nigricans Associated with Insulin Resistance

Pathophysiology and Management
  • Trinh Hermanns-Lê
  • André Scheen
  • Gérald E. Piérard
Review Article

Abstract

The association of acanthosis nigricans, skin tags, diabetes mellitus due to insulin resistance, and obesity in adolescents and young adults represents a well defined syndrome. Hyperandrogenism may also be present. The endocrine origin of this condition is beyond doubt. Insulin and insulin-like growth factor-1, and their receptors on keratinocytes are obviously involved in the complex regulations leading to the peculiar epidermal hyperplasia. This condition is unrelated to other types of acanthosis nigricans, including the congenital and the paraneoplastic types.

Control of obesity contributes largely to reverse the whole process, essentially by reducing both insulin resistance and compensatory hyperinsulinemia. Several drugs including metformin, octreotide, retinoids and topical colecalciferol (vitamin D3) analogs are also beneficial in clearing acanthosis nigricans.

Keywords

Insulin Resistance Metformin Octreotide Acromegaly Acarbose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000; 21 (5): 457–87PubMedCrossRefGoogle Scholar
  2. 2.
    Hermanns-Lê T, Hermanns JF, Piérard GE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol 2002; 19 (1): 12–4PubMedCrossRefGoogle Scholar
  3. 3.
    Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol 1994; 31 (1): 1–19PubMedCrossRefGoogle Scholar
  4. 4.
    Torly D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol 2002; 147 (6): 1096–101CrossRefGoogle Scholar
  5. 5.
    Garcia Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol 2002; 3 (7): 497–506PubMedCrossRefGoogle Scholar
  6. 6.
    Hud Jr JA, Cohen JB, Wagner JM, et al. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992; 128 (7): 941–4PubMedCrossRefGoogle Scholar
  7. 7.
    Garcia Hidalgo L, Orozco-Topete R, Gonzalez-Barranco J, et al. Dermatoses in 156 obese adults. Obes Res 1999; 7 (3): 299–302PubMedGoogle Scholar
  8. 8.
    Brockow K, Steinkraus V, Rinninger F, et al. Acanthosis nigricans: a marker for hyperinsulinemia. Pediatr Dermatol 1995; 12 (4): 323–6PubMedCrossRefGoogle Scholar
  9. 9.
    Panidis D, Skiapodopoulos S, Rousso D, et al. Association of acanthosis nigricans with insulin resistance in patients with polycystic ovary syndrome. Br J Dermatol 1995; 132 (6): 936–41PubMedCrossRefGoogle Scholar
  10. 10.
    Esperanza LE, Fenske NA. Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN) syndrome: spontaneous remission in a 15-year-old girl. J Am Acad Dermatol 1996; 34 (5 Pt 2): 892–7PubMedCrossRefGoogle Scholar
  11. 11.
    Kuroki R, Sadamoto Y, Imamura M, et al. Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control. Dermatology 1999; 198 (2): 164–6PubMedCrossRefGoogle Scholar
  12. 12.
    Matsuoka LY, Wortsman J, Gavin JR, et al. Spectrum of endocrine abnormalities associated with acanthosis nigricans. Am J Med 1987; 83 (4): 719–25PubMedCrossRefGoogle Scholar
  13. 13.
    Fradkin JE, Eastman RC, Lesniak MA, et al. Specificity spillover at the hormone receptor: exploring its role in human disease. N Engl J Med 1989; 320 (10): 640–5PubMedCrossRefGoogle Scholar
  14. 14.
    Rendon MI, Cruz Jr PD, Sontheimer RD, et al. Acanthosis nigricans: a cutaneous marker of tissue resistance to insulin. J Am Acad Dermatol 1989; 21 (3 Pt 1): 461–9PubMedCrossRefGoogle Scholar
  15. 15.
    Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes and implications. N Engl J Med 1991; 325 (13): 938–48PubMedCrossRefGoogle Scholar
  16. 16.
    Cruz Jr PD, Hud Jr JA. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98 (6 Suppl.): 82S-5SCrossRefGoogle Scholar
  17. 17.
    Humbert P, Nguyen N. Physiopathologie de l’acanthosis nigricans. Ann Dermatol Venereol 1998; 125 (11): 851–5PubMedGoogle Scholar
  18. 18.
    Verrando P, Ortonne JP. Insulin binding properties of normal and transformed human epidermal cultured keratinocytes. J Invest Dermatol 1985; 85 (4): 328–32PubMedCrossRefGoogle Scholar
  19. 19.
    Ehrmann DA. Insulin resistance and polycystic ovary syndrome. Curr Diab Rep 2002; 2 (1): 71–6PubMedCrossRefGoogle Scholar
  20. 20.
    Gambineri A, Pelusi C, Vicennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26 (7): 883–96PubMedCrossRefGoogle Scholar
  21. 21.
    Scheen AJ. Perspective in the treatment of insulin resistance. Hum Reprod 1997; 12 Suppl. 1: 63–71PubMedCrossRefGoogle Scholar
  22. 22.
    Scheen AJ, Paquot N, Letiexhe M, et al. Glucose metabolism in obese subjects: lessons from OGTT, IVGTT, and clamp studies. Int J Obes Relat Metab Disord 1995; 19 (3 Suppl.): 14S-20SGoogle Scholar
  23. 23.
    Smith U. Impaired (‘diabetic’) insulin signalling and action occur in fat cells long before glucose intolerance -is insulin resistance initiated in the adipose tissue? Int J Obes Relat Metab Disord 2002; 26 (7): 897–904PubMedCrossRefGoogle Scholar
  24. 24.
    Letiexhe MR, Scheen AJ, Gérard PL, et al. Postgastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab 1995; 80 (2): 364–9PubMedCrossRefGoogle Scholar
  25. 25.
    Felber JP, Golay A. Pathways from obesity to diabetes. Int J Obes Relat Metab Disord 2002; 26 Suppl. 2: 39S-45SCrossRefGoogle Scholar
  26. 26.
    Roemmich JN, Clark PA, Lusk M, et al. Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release. Int J Obes Relat Metab Disord 2002; 26 (5): 701–9PubMedCrossRefGoogle Scholar
  27. 27.
    Scheen AJ, Lefèvre PJ. Insulin resistance versus insulin deficiency: which one comes first? The old question revisited. In: Di Mario U, Leonetti F, Pugliese G, et al., editors. Diabetes in the new millenium. New York: Wiley & Sons, 2000: 101–13Google Scholar
  28. 28.
    Smith SR, Ravussin E. Emerging paradigms for understanding fatness and diabetes risk. Curr Diab Rep 2002; 2 (3): 223–30PubMedCrossRefGoogle Scholar
  29. 29.
    Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 Suppl. 3: 24–34PubMedCrossRefGoogle Scholar
  30. 30.
    Xu B, Bird VG, Miller WT. Substrate specificities of the insulin and insulin-like growth factor 1 receptor tyrosine kinase catalytic domains. J Biol Chem 1995; 270 (50): 29825–30PubMedCrossRefGoogle Scholar
  31. 31.
    Kim JJ, Accili D. Signalling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res 2002; 12 (2): 84–90PubMedCrossRefGoogle Scholar
  32. 32.
    Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-1 and development of glucose intolerance: a prospective observational study. Lancet 2002; 359 (9319): 1740–5PubMedCrossRefGoogle Scholar
  33. 33.
    Lee PD, Giudice LC, Conover CA, et al. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997; 216 (3): 319–57PubMedGoogle Scholar
  34. 34.
    Frystyk J, Skjaerbaek C, Vestbo E, et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 1999; 15 (5): 314–22PubMedCrossRefGoogle Scholar
  35. 35.
    Centurion SA, Schwartz RA. Cutaneous signs of acromegaly. Int J Dermatol 2002; 41 (10): 631–4PubMedCrossRefGoogle Scholar
  36. 36.
    Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003; 63 (12): 1165–84PubMedCrossRefGoogle Scholar
  37. 37.
    Tuomilehto J, Lindström J, Ericksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344 (18): 1343–50PubMedCrossRefGoogle Scholar
  38. 38.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (6): 393–403PubMedCrossRefGoogle Scholar
  39. 39.
    Schmitz KH, Jacobs Jr DR, Hong CP, et al. Association of physical activity with insulin sensitivity in children. Int J Obes Relat Metab Disord 2002; 26 (10): 1310–6PubMedCrossRefGoogle Scholar
  40. 40.
    De Bourdeaudhuij I, Crombez G, Deforche B, et al. Effects of distraction on treadmill running time in severely obese children and adolescents. Int J Obes Relat Metab Disord 2002; 26 (8): 1023–9PubMedCrossRefGoogle Scholar
  41. 41.
    Lunetta M, Di Mauro M, Le Moli R, et al. Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. J Endocrinol Invest 1996; 19 (10): 699–703PubMedGoogle Scholar
  42. 42.
    Bikle DD. Vitamin D: a calciotropic hormone regulating calcium-induced keratinocyte differentiation. J Am Acad Dermatol 1997; 37 (3 Pt 2): 42S-52SGoogle Scholar
  43. 43.
    Böhm M, Luger TA, Metze D. Acanthosis nigricans associated with transitional cell carcinoma of bladder-symptomatic treatment with calcipotriol. Hautarzt 1999; 50 (8): 593–6PubMedGoogle Scholar
  44. 44.
    Akovbyan VA, Talanin NY, Arifov SS, et al. Successful treatment of acanthosis nigricans with etretinate. J Am Acad Dermatol 1994; 31 (1): 118–20PubMedCrossRefGoogle Scholar
  45. 45.
    Tankova T, Koev D, Dakovska L, et al. Therapeutic approach in insulin resistance with acanthosis nigricans. Int J Clin Pract 2002; 56 (8): 578–81PubMedGoogle Scholar
  46. 46.
    DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131 (4): 281–303PubMedGoogle Scholar
  47. 47.
    Grigorescu F, Poucheret P, Bouix O, et al. Metformin potentiates phosphatidylinositol-3′ kinase by IRS-2 recruitment in rat hepatic tissue. Diabetologia 1998; 41 Suppl. 1: 189AGoogle Scholar
  48. 48.
    Rique S, Ibanez L, Marcos MV, et al. Effects of metformin on androgens and insulin concentrations in type A insulin resistance syndrome. Diabetologia 2000; 43 (3): 385–6PubMedCrossRefGoogle Scholar
  49. 49.
    Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335 (9): 617–23PubMedCrossRefGoogle Scholar
  50. 50.
    Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107 (4): E55CrossRefGoogle Scholar
  51. 51.
    Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359 (9323): 2072–7PubMedCrossRefGoogle Scholar
  52. 52.
    Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160 (9): 1321–6PubMedCrossRefGoogle Scholar
  53. 53.
    Rosenbloom AL, Joe JR, Young RS, et al. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999; 22 (2): 345–54PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Trinh Hermanns-Lê
    • 1
  • André Scheen
    • 1
  • Gérald E. Piérard
    • 1
  1. 1.Departments of Dermatopathology and Diabetes, Nutrition and Metabolic DisordersUniversity of LiègeLiègeBelgium

Personalised recommendations